News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Is baricitinib safer than TNFi for RA patients at risk of VTE?
a day ago
byStephen Padilla
Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients enriched for venous thromboembolism (VTE) risk factors with high baseline disease activity, reports a study.
Is baricitinib safer than TNFi for RA patients at risk of VTE?
a day ago
Novel extended-release tablet superior to febuxostat at reducing SUA levels
a day ago
byStephen Padilla
An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.







